加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.7822
−US$0.0098 · -1.24%
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
前收盘价
US$0.7822
−US$0.0098 · -1.24%
盘前
US$0.77
−US$0.0122 · -1.56%
10月12日 7:08 ET
盘中时间采用ET。市场数据可能有所延迟。
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
日内区间
当前US$0.7822
52周区间
当前US$0.7822
盘中时间采用ET。市场数据可能有所延迟。
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
日内区间
当前US$0.7822
52周区间
当前US$0.7822
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 |
|---|---|---|---|
| 研究与开发 | 125.53万 USD | 210.34万 USD | 552.89万 USD |
| 销售、一般及管理费用 | 251.25万 USD | 191.72万 USD | 309.62万 USD |
| 营业费用 | 377.24万 USD | 402.68万 USD | 863.67万 USD |
| 利息收入 | 2.56万 USD | 14.26万 USD | 36.01万 USD |
| 利息支出 | 10.09万 USD | 5000 USD | 1万 USD |
| 折旧和摊销 | 12万 USD | 11.86万 USD | 12.1万 USD |
| 营业利润 | −377.24万 USD | −402.68万 USD | −863.67万 USD |
| 净利润 | −384.76万 USD | −485.54万 USD | −828.2万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
